TenSixteen Bio is the first company to leverage somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related diseases. We are a precision platform therapeutics company utilizing novel genomic biology across multiple disease areas. TenSixteen was conceived around the promise of leveraging unique data assets and capabilities to drive discovery and novel clinical development paradigms, and we are building a genomics and data science platform that will enable data integration and generation to support these efforts.
We aim to transform the future of precision medicine in complex diseases.
Company Details
- Employees
- 5
- Founded
- -
- Address
- San Francisco, Ca 94549, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.tensixteen.bio
- HQ
- San Francisco, CA
Tensixteen Bio Questions
Tensixteen Bio's website is http://www.tensixteen.bio
Tensixteen Bio's LinkedIn profile is https://www.linkedin.com/company/tensixteenbio
Tensixteen Bio has
5 employees.
View email and phone details for 5
employees at Tensixteen Bio.
Tensixteen Bio's industry is
Biotechnology Research
Tensixteen Bio's top competitors are
Precede Biosciences,
Scorpion Therapeutics,
Hepatx Corporation,
Foresite Capital,
Calico Life Sciences,
Xaira Therapeutics,
Foresite Labs,
Interline Therapeutics,
Newco,
Forty Seven Inc..
Tensixteen Bio's categories are Biotechnology Research
Tensixteen Bio's founding year is 2020
